Anika Therapeutics (ANIK) Fundamental Analysis: Revenue, Earnings & Valuation

0.26 / 10

Underperform

Fundamental rating is Underperform with a 0.3/10 score. Profit‑MV and net cash‑flow ratios are positive, yet Revenue‑MV, Cash‑MV and EBIT ratios are negative, dragging the outlook. Overall, fundamentals are concerning and warrant prudence.

Analysis Checks(6/10)

Revenue-MV

Value0.15

Score0/3

Weight114.00%

1M Return-4.18%

ROA (%)

Value-5.54

Score2/3

Weight-21.01%

1M Return0.64%

Net cash flow from operating activities / Operating revenue (%)

Value9.92

Score2/3

Weight-49.88%

1M Return1.48%

Profit-MV

Value0.66

Score2/3

Weight-107.67%

1M Return3.09%

Annualized net profit margin on total assets (%)

Value-5.54

Score2/3

Weight-21.01%

1M Return0.64%

EBIT / Total operating revenue (%)

Value-1049.47

Score0/3

Weight126.25%

1M Return-5.19%

Asset-MV

Value-0.55

Score1/3

Weight-11.50%

1M Return0.38%

Net profit / Total operating revenue (%)

Value-9.64

Score3/3

Weight-47.94%

1M Return1.41%

Cash-MV

Value-0.29

Score1/3

Weight102.07%

1M Return-4.16%

Net profit / Total profit (%)

Value116.90

Score2/3

Weight16.68%

1M Return-0.54%

Is ANIK undervalued or overvalued?

ANIK scores 0.26/10 on fundamentals and holds a Premium valuation at present. Backed by its -7.32% ROE, -9.64% net margin, -18.18 P/E ratio, 1.38 P/B ratio, and 80.16% earnings growth, these metrics solidify its Underperform investment rating.